AstraZeneca  3Q Revenues: $6.3 billion (-6%) 3Q Earnings: $1.2 billion (-27%) YTD Revenues: $20.7 billion (-9%) YTD Earnings: $3.1 billion (-26%) Comments: The impact from products that recently lost exclusivity is estimated at $350 million in the quarter. U.S. revenues were down 8% with declines in Crestor (-11% to $1.4 billion) and Nexium (-5% to $918 million), partially offset by growth for Symbicort (+7% to $839 million), the diabetes franchise, FluMist (+30% to $188 million) and Brilin...